AVROBIO INC's ticker is AVRO and the CUSIP is 05455M100. A total of 100 filers reported holding AVROBIO INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,515 | -70.4% | 1,515 | -78.9% | 0.00% | – |
| Q4 2022 | $5,119 | -14.7% | 7,181 | -24.7% | 0.00% | – |
| Q3 2022 | $6,000 | -33.3% | 9,541 | +1.8% | 0.00% | – |
| Q2 2022 | $9,000 | -99.7% | 9,370 | -99.6% | 0.00% | -100.0% |
| Q1 2022 | $3,233,000 | -67.6% | 2,449,015 | -5.6% | 0.01% | -63.2% |
| Q4 2021 | $9,993,000 | -25.0% | 2,595,453 | +8.7% | 0.02% | -24.0% |
| Q3 2021 | $13,327,000 | -38.2% | 2,388,380 | -1.5% | 0.02% | -37.5% |
| Q2 2021 | $21,557,000 | -25.5% | 2,424,952 | +6.3% | 0.04% | -28.6% |
| Q1 2021 | $28,943,000 | +65.7% | 2,280,771 | +82.0% | 0.06% | +55.6% |
| Q4 2020 | $17,467,000 | +94.7% | 1,253,000 | +81.8% | 0.04% | +71.4% |
| Q3 2020 | $8,973,000 | +79.0% | 689,127 | +139.9% | 0.02% | +75.0% |
| Q2 2020 | $5,012,000 | +13089.5% | 287,200 | +15225.5% | 0.01% | – |
| Q4 2019 | $38,000 | +3700.0% | 1,874 | +2185.4% | 0.00% | – |
| Q3 2019 | $1,000 | -50.0% | 82 | -17.2% | 0.00% | – |
| Q4 2018 | $2,000 | – | 99 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 4,520,863 | $5,968,000 | 0.76% |
| Aisling Capital Management LP | 1,009,779 | $1,333,000 | 0.72% |
| MPM BioImpact LLC | 647,918 | $855,000 | 0.23% |
| GMT CAPITAL CORP | 2,594,914 | $3,425,000 | 0.22% |
| New Leaf Venture Partners, L.L.C. | 315,550 | $417,000 | 0.21% |
| GSA CAPITAL PARTNERS LLP | 338,422 | $447,000 | 0.06% |
| Penn Mutual Asset Management, LLC | 37,306 | $49,000 | 0.06% |
| Eversept Partners, LP | 295,369 | $389,887 | 0.03% |
| XTX Topco Ltd | 23,289 | $31,000 | 0.01% |
| Colonial River Wealth Management, LLC | 17,636 | $23,000 | 0.01% |